NCT00189722CompletedPhase 2
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
Astellas Pharma Inc28 sites in 5 countries160 target enrollmentStarted: September 19, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 160
- Locations
- 28
Study Overview
Brief Summary
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of asthma
- •Patients treated with inhaled corticosteroid and long acting beta 2 agonist
- •FEV1(forced expiratory volume in 1 second)>50% to 80%
Exclusion Criteria
- •Respiratory infection within 2weeks
- •Asthma exacerbation within 6 weeks
Investigators
Study Sites (28)
Loading locations...
Similar Trials
Completed
Phase 2
Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent AsthmaAsthma, BronchialBronchial AsthmaNCT00189787Astellas Pharma Inc370
Completed
Phase 2
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent AsthmaAsthmaNCT00116103Astellas Pharma Inc
Recruiting
Not Applicable
Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia GravisMyasthenia GravisNCT04768465Da, Yuwei, M.D.160
Completed
Not Applicable
Exacerbation Risk in AsthmaAsthmaNCT05501639Boehringer Ingelheim1,899
Completed
Phase 2
A Safety and Efficacy Study of Tralokinumab in Adults With AsthmaAsthmaNCT01402986MedImmune LLC689